Signal loss in DCE-MRI associated with tumor progression in prostate cancer bone metastasis model
Dafni H, Panda K, Ronen S, Kim S, Bankson J
The University of Texas, MD Anderson Cancer Center
Bone metastases are often resistant to conventional therapy, but response can be improved by combination with anti-vascular agents. A bone metastasis model was induced by intratibial injection of human prostate cancer cells (PC-3MM2). Dynamic contrast enhanced (DCE)-MRI using macromolecular contrast material (biotin-BSA-GdDTPA) showed progressive signal loss in the bone marrow, matching the progression of bone metastases. Loss of signal could be attributed to the increased interstitial fluid pressure in the tumor microenvironment. Extravasation of contrast material occurred only after osteolysis. These apparent vascular changes suggest that DCE-MRI could be used to monitor disease progression and drug-induced regression of bone metastases.